Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 5/2020

01-05-2020 | Carbapenem Antibiotic | Original Article

Comparison of nine different selective agars for the detection of carbapenemase-producing Enterobacterales (CPE)

Authors: Stephan Göttig, Sarah V. Walker, Ahmad Saleh, Florian Koroska, Julian Sommer, Yvonne Stelzer, Joerg Steinmann, Axel Hamprecht

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 5/2020

Login to get access

Abstract

The rapid identification of patients colonized with carbapenem-resistant Enterobacterales (CRE) is important for infection control purposes. Here, we compared and evaluated nine different agars for the detection of carbapenemase-producing Enterobacterales (CPE) from clinical samples. In the study, 69 CPE and 40 carbapenemase-negative isolates were included. Overall, seven commercially available screening agars were assessed: Brilliance CRE (Oxoid), Chromatic CRE (Liofilchem), chromID CARBA and chromID OXA-48 (both bioMérieux), three ESBL agars (Chromatic ESBL [Liofilchem], chromID ESBL [bioMérieux], Brilliance ESBL [Oxoid]), and two agars produced in-house (McCARB and McCARB-T). The sensitivity of CRE agars for CPE detection ranged from 34.8 to 98.6%. Brilliance CRE and McCARB/McCARB-T showed the overall highest sensitivity (98.6 and 97.1%, respectively). OXA-48 producers were the most difficult to detect; only 4/9 agars detected all isolates (McCARB/McCARB-T, Chromatic CRE, ChromID OXA-48). Additionally, all ESBL-negative OXA-48 isolates failed to grow on ESBL screening agars. Specificity ranged from 30 (Brilliance ESBL) to 100% (ChromID OXA-48). The limit of detection for different CPE in spiked stool samples ranged from 1.5 × 101 to 1.5 × 103 CFU/ml. Overall, Brilliance CRE and the McCARB in-house agars showed the best performance and were able to detect most CPE, including almost all OXA-48. ESBL agars were not suitable for detection of CPE alone, as OXA-48 isolates negative for ESBL were suppressed. The highest sensitivity was achieved by a combination of a CRE agar and an ESBL agar.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lutgring JD, Limbago BM (2016) The problem of carbapenemase-producing-carbapenem-resistant-Enterobacteriaceae detection. J Clin Microbiol 54:529–534CrossRef Lutgring JD, Limbago BM (2016) The problem of carbapenemase-producing-carbapenem-resistant-Enterobacteriaceae detection. J Clin Microbiol 54:529–534CrossRef
2.
go back to reference Grundmann H, Glasner C, Albiger B et al (2017) Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis 17:153–163CrossRef Grundmann H, Glasner C, Albiger B et al (2017) Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis 17:153–163CrossRef
3.
go back to reference Jazmati N, Hein R, Hamprecht A (2016) Use of an enrichment broth improves detection of extended-Spectrum-Beta-lactamase-producing Enterobacteriaceae in clinical stool samples. J Clin Microbiol 54:467–470CrossRef Jazmati N, Hein R, Hamprecht A (2016) Use of an enrichment broth improves detection of extended-Spectrum-Beta-lactamase-producing Enterobacteriaceae in clinical stool samples. J Clin Microbiol 54:467–470CrossRef
4.
go back to reference Pence MA, Hink T, Burnham C-AD (2015) Comparison of chromogenic media for recovery of carbapenemase-producing Enterobacteriaceae (CPE) and evaluation of CPE prevalence at a tertiary care academic medical center. J Clin Microbiol 53:663–666CrossRef Pence MA, Hink T, Burnham C-AD (2015) Comparison of chromogenic media for recovery of carbapenemase-producing Enterobacteriaceae (CPE) and evaluation of CPE prevalence at a tertiary care academic medical center. J Clin Microbiol 53:663–666CrossRef
5.
go back to reference Papadimitriou-Olivgeris M, Bartzavali C, Christofidou M et al (2014) Performance of chromID® CARBA medium for carbapenemases-producing Enterobacteriaceae detection during rectal screening. Eur J Clin Microbiol Infect Dis 33:35–40CrossRef Papadimitriou-Olivgeris M, Bartzavali C, Christofidou M et al (2014) Performance of chromID® CARBA medium for carbapenemases-producing Enterobacteriaceae detection during rectal screening. Eur J Clin Microbiol Infect Dis 33:35–40CrossRef
6.
go back to reference Koroska F, Göttig S, Kaase M, Steinmann J, Gatermann S, Sommer J, Wille T, Plum G, Hamprecht A (2017) Comparison of phenotypic tests and an immunochromatographic assay and development of a new algorithm for detection of OXA-48-like carbapenemases. J Clin Microbiol 55:877–883CrossRef Koroska F, Göttig S, Kaase M, Steinmann J, Gatermann S, Sommer J, Wille T, Plum G, Hamprecht A (2017) Comparison of phenotypic tests and an immunochromatographic assay and development of a new algorithm for detection of OXA-48-like carbapenemases. J Clin Microbiol 55:877–883CrossRef
8.
go back to reference Hamprecht A, Vehreschild JJ, Seifert H, Saleh A (2018) Rapid detection of NDM, KPC and OXA-48 carbapenemases directly from positive blood cultures using a new multiplex immunochromatographic assay. PLoS One 13:e0204157CrossRef Hamprecht A, Vehreschild JJ, Seifert H, Saleh A (2018) Rapid detection of NDM, KPC and OXA-48 carbapenemases directly from positive blood cultures using a new multiplex immunochromatographic assay. PLoS One 13:e0204157CrossRef
9.
go back to reference Hamprecht A, Poirel L, Göttig S, Seifert H, Kaase M, Nordmann P (2013) Detection of the carbapenemase GIM-1 in Enterobacter cloacae in Germany. J Antimicrob Chemother 68:558–561CrossRef Hamprecht A, Poirel L, Göttig S, Seifert H, Kaase M, Nordmann P (2013) Detection of the carbapenemase GIM-1 in Enterobacter cloacae in Germany. J Antimicrob Chemother 68:558–561CrossRef
Metadata
Title
Comparison of nine different selective agars for the detection of carbapenemase-producing Enterobacterales (CPE)
Authors
Stephan Göttig
Sarah V. Walker
Ahmad Saleh
Florian Koroska
Julian Sommer
Yvonne Stelzer
Joerg Steinmann
Axel Hamprecht
Publication date
01-05-2020
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 5/2020
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-019-03786-7

Other articles of this Issue 5/2020

European Journal of Clinical Microbiology & Infectious Diseases 5/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.